| Literature DB >> 29460415 |
Simona Volpi1, Carol J Bult2, Rex L Chisholm3, Patricia A Deverka4, Geoffrey S Ginsburg5, Howard J Jacob6, Melpomeni Kasapi1, Howard L McLeod7, Dan M Roden8, Marc S Williams9, Eric D Green1, Laura Lyman Rodriguez1, Samuel Aronson10, Larisa H Cavallari11, Joshua C Denny12, Lynn G Dressler13, Julie A Johnson11, Teri E Klein14, J Steven Leeder15, Micheline Piquette-Miller16, Minoli Perera17, Laura J Rasmussen-Torvik18, Heidi L Rehm19, Marylyn D Ritchie20, Todd C Skaar21, Nikhil Wagle22, Richard Weinshilboum23, Kristin W Weitzel24, Robert Wildin25, John Wilson26, Teri A Manolio1, Mary V Relling27.
Abstract
Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.Entities:
Mesh：
Year: 2018 PMID： 29460415 PMCID： PMC5902434 DOI： 10.1002/cpt.1048
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875